H. Res. 775 is a House resolution that supports designating September 2025 as "National Ovarian Cancer Awareness Month." It collects findings on incidence, mortality, survival by stage, the absence of a reliable early detection test, symptom awareness, hereditary risk (including BRCA), low compliance with genetic testing guidelines, and disparities in outcomes for Black women, low-income women, and rural residents.
The resolution is declaratory: it endorses awareness goals and summarizes clinical and epidemiological data but does not appropriate funds, create new programs, or impose regulatory requirements. Professionals should treat this as a signaling instrument that can influence public outreach, advocacy activity, and the priorities of agencies or funders — and that may increase demand for genetic counseling, testing, and provider education without delivering corresponding resources or metrics for evaluation.
At a Glance
What It Does
The resolution expresses the House’s support for designating September 2025 as National Ovarian Cancer Awareness Month and lists multiple findings about the disease, from incidence and survival statistics to clinical guidance and access gaps. It contains no statutory obligations, appropriations, or reporting mandates; it is symbolic.
Who It Affects
Patients and survivors, advocacy organizations, clinicians (especially primary care and gynecologic oncology), genetic counselors and diagnostic labs, federal health agencies, and health systems in underserved and rural areas are the primary audiences and potential indirect beneficiaries. The resolution explicitly references women on Active Duty and underserved populations.
Why It Matters
Formal recognition raises the profile of ovarian cancer in public health messaging and can be used by advocates to justify programmatic and funding requests. It also highlights specific operational issues—low genetic testing compliance, lack of early detection, and racial and geographic disparities—that could prompt clinical, payer, and program responses even though the resolution itself imposes no requirements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 775 is a single-purpose, declaratory House resolution that supports naming September 2025 as National Ovarian Cancer Awareness Month.
It compiles a series of "whereas" findings that summarize current estimates of cases and deaths, survival differentials by stage, symptom lists, and key clinical recommendations. The document is not a law; it neither creates programs nor provides funds — instead it frames ovarian cancer as a public-health issue deserving heightened attention.
The text emphasizes clinical realities that shape why awareness matters: the overall five-year survival is modest, early-stage diagnosis has dramatically higher survival, and there is currently no reliable early screening test comparable to mammography or Pap smears. The resolution lists common symptoms (bloating, pelvic/abdominal pain, early satiety, urinary changes) and notes that these symptoms are often vague and easily misattributed, which contributes to late-stage detection in approximately 80 percent of cases.The resolution also draws attention to hereditary risk and clinical guidance: it cites that roughly one-fifth of ovarian cancers have a hereditary component, references BRCA-related risk increases, and repeats professional guidance that individuals diagnosed with ovarian cancer should receive genetic counseling and testing.
At the same time, it flags empiric gaps — for example, historically low compliance with testing guidance — and points to underfunding of ovarian cancer research relative to mortality.Finally, H. Res. 775 spotlights disparities and data issues.
It notes higher late-stage diagnoses and lower five-year survival for Black women, access barriers for women of color, low-income and rural populations, and an elevated share of younger cases among Active Duty women. By packaging these findings into a nationally designated awareness month, the resolution invites outreach campaigns and can be used to pressure agency action or philanthropic investment, but it leaves the follow-through — funding, program design, measurement — to other actors.
The Five Things You Need to Know
H. Res. 775, introduced on September 30, 2025 by Rep. Rosa DeLauro (with Rep. Bacon), is a House resolution supporting the designation of September 2025 as National Ovarian Cancer Awareness Month.
The text cites American Cancer Society estimates for 2025 of 20,890 new ovarian cancer cases and 12,730 deaths nationwide.
It records an overall 5-year ovarian cancer survival rate of 51.6 percent and notes survival exceeds 90 percent for cases diagnosed at early stages, while roughly 80 percent of cases are detected at an advanced stage due to lack of a reliable early screening test.
The resolution repeats professional guidance (NCCN and Society of Gynecologic Oncology) that all individuals diagnosed with ovarian cancer should receive genetic counseling and testing, and cites research showing only about one-third of survivors received such testing in 2013–2014.
The measure is declaratory and nonbinding: it supports goals and awareness activities but creates no new funding, reporting requirements, or statutory authority.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on the scale and lethality of ovarian cancer
These opening findings assemble core epidemiological figures — lifetime risk (~1 in 91), expected 2025 case and death counts, and aggregate five-year survival. For practitioners and program planners, this clause supplies the statistics advocates will use when pitching awareness campaigns or grant proposals; legally, it functions only as a preamble and carries no implementation demands.
Statements about lack of early detection and symptom profile
The resolution explicitly contrasts ovarian cancer with breast and cervical screening tools and lists typical but nonspecific symptoms. That framing underpins the policy argument for awareness: because there is no reliable screening test, improving symptom recognition among the public and clinicians is presented as the primary lever to shift stage at diagnosis. The clause therefore sets expectations for the types of outreach activities stakeholders are likely to undertake.
Documentation of racial, geographic, and data-collection inequities
These provisions call out higher late-stage diagnoses and worse five-year mortality among Black women, barriers faced by women of color, low-income patients, and rural residents, and difficulties in collecting treatment and outcome data. Practically, the clause is an evidence base that advocates can cite when seeking targeted interventions or equity-focused funding; it does not, however, provide tools for improving surveillance or data systems.
References to BRCA, genetic counseling/testing, and prophylactic options
The resolution highlights that approximately 20 percent of ovarian cancers have a hereditary component, notes BRCA-associated risk increases, and points to guideline recommendations for universal genetic counseling/testing among diagnosed individuals. It also mentions prophylactic measures such as opportunistic salpingectomy. This section reinforces clinical best-practice messaging but stops short of mandating provider behavior or insurer coverage.
Designation and endorsement
The resolution’s operative language contains two brief clauses: a declaration supporting the designation of September 2025 as National Ovarian Cancer Awareness Month, and an endorsement of the month’s goals and ideals. These clauses have no legal force beyond expression of the House’s viewpoint, but they formalize Congressional support that advocacy groups can leverage in communications and fundraising.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Women at risk and ovarian cancer survivors — Greater public messaging can improve symptom recognition and potentially shorten diagnostic delays for some individuals, which matters given the survival differential by stage.
- Advocacy and research organizations (e.g., Ovarian Cancer Research Alliance) — A congressional designation provides visibility that can amplify fundraising, awareness events, and policy advocacy.
- Primary care clinicians and gynecologic providers — The resolution’s emphasis on symptom awareness and family-history assessment may justify clinician education and practice improvements to prompt earlier evaluation.
- Genetic counselors and diagnostic labs — Reiterated guidance favoring universal genetic counseling/testing for diagnosed individuals could increase referrals and test utilization if providers act on the messaging.
- Military and VA health systems — The text’s specific reference to a higher proportion of younger cases among Active Duty women spotlights a subgroup that could receive targeted outreach or review of military clinical protocols.
Who Bears the Cost
- Health systems and clinics — Increased public awareness may drive more patients to seek evaluation and genetic counseling/testing, straining capacity and potentially increasing uncompensated care in under-resourced settings.
- Genetic counseling services and labs — A rise in demand for testing could require scaling personnel and infrastructure, with attendant training and reimbursement challenges.
- State and local public health departments and community organizations — These groups may be expected to run awareness campaigns or screenings without accompanying federal funding, shifting costs to local budgets or philanthropic channels.
- Payers and insurers — If awareness campaigns lead to more requests for genetic testing, prophylactic procedures, or early diagnostic workups, payers may face higher utilization and associated coverage decisions (though the resolution does not change coverage law).
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus material change: the resolution elevates ovarian cancer on the national agenda and pressures stakeholders to act, but without funding, mandates, or data infrastructure the designation may increase expectations and demand without producing equitable improvements in diagnosis, treatment, or survival.
H. Res. 775 is primarily symbolic: it aggregates clinical and epidemiological findings and endorses an awareness month but does not allocate resources, require agencies to act, or establish performance metrics.
That limits its direct impact on outcomes; its power lies in signaling and agenda-setting rather than in changing care delivery or surveillance infrastructure. For stakeholders seeking measurable change, the resolution is a first step that will need follow-on legislation, appropriations, or administrative action to convert awareness into sustained services or research investment.
The resolution also raises a recurring implementation tension: urging broader genetic testing and awareness without addressing access, workforce capacity, or insurer coverage risks widening disparities. Encouraging more people to seek genetic counseling and prophylactic care can improve outcomes for those who can access services, but it can also increase unmet demand among rural, low-income, and uninsured populations.
Finally, the document identifies data-collection gaps but contains no mechanism to improve registries or disaggregated outcome reporting; without that, policymakers and researchers will have a harder time measuring whether awareness campaigns actually reduce late-stage diagnoses or mortality.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.